<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004675</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-012</org_study_id>
    <nct_id>NCT05004675</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients</brief_title>
  <acronym>LIBerate-VI</acronym>
  <official_title>Randomized Open Label, Phase 3 Study to Compare the Efficacy and Safety of Lerodalcibep (LIB003) to Inclisiran in Patients at Very High or High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of LDL-C reductions of lerodalcibep (LIB003) 300 mg to inclisiran (Leqvio®) 284 in&#xD;
      patients at very-high risk or high-risk for CVD on stable diet and oral LDL-C-lowering drug&#xD;
      therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Open Label (lipids blinded), Phase 3 Study to Evaluate the Efficacy and Safety of&#xD;
      Lerodalcibep (LIB003) at Day 270 of subcutaneous (SC) monthly (QM [≤31 days]) lerodalcibep&#xD;
      (LIB003) 300 mg administered to SC inclisiran (Leqvio®) 284 mg at Days 1 and 90 in patients&#xD;
      with very-high risk or high-risk CVD or at high risk for CVD with LDL-C ≥85 mg/dL on a stable&#xD;
      diet and oral LDL-C-lowering drug therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, comparative trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>efficacy parameters (lipids) blinded after randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C change</measure>
    <time_frame>Day 270</time_frame>
    <description>Percent LDL-C change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>270 days</time_frame>
    <description>frequency and severity of injection site reactions (ISRs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free PCSK9 levels</measure>
    <time_frame>Day 270</time_frame>
    <description>Percent change in free PCSK9 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoproteins</measure>
    <time_frame>Day 270</time_frame>
    <description>Percent change in Apo B and Lp(a) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment goal achievement</measure>
    <time_frame>Day 270</time_frame>
    <description>Percent of patients reaching ESC/EAS treatment goals</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Atherosclerotic Ischemic Disease</condition>
  <arm_group>
    <arm_group_label>lerodalcibep</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg SC dosed monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inclisiran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>284 mg SC dosed Day 1 and Day 90</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lerodalcibep</intervention_name>
    <description>300 mg</description>
    <arm_group_label>lerodalcibep</arm_group_label>
    <other_name>LIB003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclisiran</intervention_name>
    <description>284 mg</description>
    <arm_group_label>inclisiran</arm_group_label>
    <other_name>Leqvio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed informed consent prior to any study-specific procedure;&#xD;
&#xD;
          -  Weight of ≥40 kg (88 lb) and body mass index (BMI) ≥16 and ≤42 kg/m2;&#xD;
&#xD;
          -  Very- high or high risk for CVD as defined in 2019 ESC/EAS Guidelines&#xD;
&#xD;
          -  High-intensity statin (daily atorvastatin 40/80 or rosuvastatin 20/40) without other&#xD;
             acceptable oral lipid lowering treatment plus diet; stable &gt;4 weeks with LDL-C ≥85&#xD;
             mg/dL and triglycerides ≤400 mg/dL&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must continue using a highly effective form of&#xD;
             birth control if sexually active&#xD;
&#xD;
          -  Males whose partners are of CBP and not using a highly effective form of birth control&#xD;
             will either be surgically sterile or agree to use the following forms of&#xD;
             contraception, male or female condom with spermicide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or active clinical condition or acute and/or unstable systemic disease,&#xD;
             including cancer, compromising patient inclusion or preclude completion of the study,&#xD;
             at the discretion of the Investigator&#xD;
&#xD;
          -  Homozygous FH&#xD;
&#xD;
          -  non-high intensity statins, mipomersen, lomitapide, gemfibrozil, and bempedoic acid&#xD;
&#xD;
          -  PCSK9 mAb within 4 weeks of screening or siRNA within 1 year&#xD;
&#xD;
          -  Severe renal dysfunction, defined eGFR &lt;30 ml/min&#xD;
&#xD;
          -  Recent, within 3 months of screening, atherosclerotic event or intervention&#xD;
&#xD;
          -  planned cardiac procedure&#xD;
&#xD;
          -  NYHA class III or IV heart failure&#xD;
&#xD;
          -  active liver disease&#xD;
&#xD;
          -  uncontrolled diabetes defined as fasting glucose &gt;200 mg/dL and HbA1c &gt; 9%&#xD;
&#xD;
          -  uncontrolled BP ≥180 mmHg systolic or ≥110 mmHg diastolic;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan A Stein, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evan A Stein, MD PhD</last_name>
    <phone>8596533141</phone>
    <email>estein@libtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Kallend, MB BS</last_name>
    <phone>+41791741830</phone>
    <email>dkallend@libtherapeutics.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lerodalcibep</keyword>
  <keyword>PCSK9 inhibitor</keyword>
  <keyword>inclisiran</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

